Contribution of cytochrome P-4502 D 6 phenotype to the neuromodulatory effects of dextromethorphan DESMEULES ,

Dextromethorphan (DEM)-mediated N-methyl-D-aspartate receptor blockade may result from an action of unchanged DEM or its active metabolite, dextrorphan (DOR). In humans, DEM is metabolized into DOR by the polymorphic enzyme CYP2D6. We therefore investigated the impact of quinidine (Qd), a selective inhibitor of CYP2D6, on DEM disposition and the contribution of CYP2D6 phenotype on DEM antinociceptive and neuromodulatory effects. Using a randomized, double-blind, crossover, placebo-controlled design, healthy volunteers (n = 7) received Qd (50 mg Qd sulfate orally) or a placebo and, 12 h later, either DEM (50 mg DEM hydrobromide orally) or a placebo. DEM and DOR pharmacodynamics were assessed for their antinociceptive and neuromodulatory effects. Antinociceptive effects were assessed over 4 h by subjective pain threshold and RIII nociceptive reflex (RIII) monitoring. Neuromodulatory effects were studied using the primary and secondary hyperalgesia induced by the topical application of capsaicin. Two of seven subjects were genotypic CYP2D6 PM. Pretreatment of EM by Qd suppressed DOR formation and increased the plasma level [...] DESMEULES, Jules Alexandre, et al. Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 288, no. 2, p. 607-612

[1]  D. Stillman High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia , 1997 .

[2]  A. Malmberg,et al.  Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  G. Steinberg,et al.  Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients. , 1996, Journal of neurosurgery.

[4]  V. Kimiskidis,et al.  Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients , 1996, Acta neurologica Scandinavica.

[5]  A. Pertovaara,et al.  An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist , 1995, Pharmacology Biochemistry and Behavior.

[6]  L. Arendt-Nielsen,et al.  Facilitation of the human nociceptive reflex by stimulation of A beta-fibres in a secondary hyperalgesic area sustained by nociceptive input from the primary hyperalgesic area. , 1995, Acta physiologica Scandinavica.

[7]  E. Sellers,et al.  Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  F. Tortella,et al.  σ receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures , 1995, Brain Research.

[9]  D. Price,et al.  The N-methyl-d-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man , 1994, Pain.

[10]  A. Jadad,et al.  Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design , 1994, Pain.

[11]  G. Bennett,et al.  Neuropathic pain sensations are differentially sensitive to dextrorphan , 1994, Neuroreport.

[12]  M. Koltzenburg,et al.  Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. , 1994, Brain : a journal of neurology.

[13]  A. Pertovaara,et al.  Capsaicin-induced central facilitation of a nociceptive flexion reflex in humans , 1993, Neuroscience Letters.

[14]  P. Pflimlin,et al.  Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. , 1993, European journal of pharmacology.

[15]  W. Löscher,et al.  Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. , 1993, European journal of pharmacology.

[16]  L. Arendt-Nielsen,et al.  Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? , 1993, Pain.

[17]  L. Bertilsson,et al.  Relationship between personality and debrisoquine hydroxylation capacity , 1993, Acta psychiatrica Scandinavica.

[18]  M. Koltzenburg,et al.  Dynamic and static components of mechanical hyperalgesia in human hairy skin , 1992, Pain.

[19]  J. Jaffe,et al.  Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan , 1991, Pharmacology Biochemistry and Behavior.

[20]  Clifford J. Woolf,et al.  The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states , 1991, Pain.

[21]  J. Willer Exploration clinique de la nociception par des techniques de réflexologie , 1990, Neurophysiologie Clinique/Clinical Neurophysiology.

[22]  P. Bechtel,et al.  Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. , 1989, British journal of clinical pharmacology.

[23]  P. Dayer,et al.  Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity , 1989, Clinical pharmacology and therapeutics.

[24]  H. Handwerker,et al.  Selective excitation by capsaicin of mechano-heat sensitive nociceptors in rat skin , 1988, Brain Research.

[25]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[26]  D. Prince,et al.  Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-d-aspartate in brain slices , 1988, Neuroscience Letters.

[27]  D. Greenberg,et al.  Dextromethorphan and dextrorphan as calcium channel antagonists , 1988, Brain Research.

[28]  A. Dickenson,et al.  Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following c fibre stimulation. , 1987, Neuropharmacology.

[29]  G. Cardinale,et al.  Morphine and codeine are endogenous components of human cerebrospinal fluid. , 1987, Life sciences.

[30]  J. Woodworth,et al.  Bioavailability Evaluation of a Controlled‐Release Dextromethorphan Liquid , 1987, Journal of clinical pharmacology.

[31]  Patrick D. Wall,et al.  Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input , 1987, Nature.

[32]  P. Kenins Responses of single nerve fibres to capsaicin applied to the skin , 1982, Neuroscience Letters.

[33]  J. Willer,et al.  Comparative study of perceived pain and nociceptive flexion reflex in man , 1977, Pain.

[34]  P. Dayer,et al.  Impact of environmental and genetic factors on codeine analgesia , 2004, European Journal of Clinical Pharmacology.

[35]  T. Leemann,et al.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers , 2004, European Journal of Clinical Pharmacology.

[36]  P. Dayer,et al.  Contribution of monoaminergic modulation to the analgesic effect of tramadol. , 1996, British journal of clinical pharmacology.

[37]  J. Idänpään-Heikkilä,et al.  WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator. , 1994, Annals of medicine.

[38]  P. Dayer,et al.  Objective assessment of clonidine analgesia in man and influence of naloxone. , 1990, Life sciences.

[39]  G. Pfaff,et al.  Pharmacogenetics of dextromethorphan O-demethylation in man. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[40]  J. Besson,et al.  [Peripheral and spinal mechanisms of nociception]. , 1986, Revue neurologique.